Thoracic radiation therapy and concomitant low-dose daily paclitaxel in non-small cell lung cancer: A phase I study

Oncology Reports

Volumn 14, Issue 6, 2005, Pages 1647-1653

  Gobitti, Carlo ^a   Franchin, Giovanni ^a   Minatel, Emilio ^a   Gigante, Marco ^a   Basso, Barbara ^a   Bujor, Laurentiu ^b   Trovò, Mauro G ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

Non small cell lung cancer; Paclitaxel; Radiation sensitizing agents; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RADIATION DOSE; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33644701840     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.6.1647     Document Type: Article

References (41)

1. Rowinsky EK: Clinical pharmacology of Taxol. J Natl Cancer Inst Monogr 15: 25-37, 1993.
2. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979. (Pubitemid 9114288)
3. Huizing MT, Misser VH, Pieters RC, et al: Taxanes: a new class of antitumor agents. Cancer Invest 13: 381-404, 1995.
4. Guenard D, Guéritte-Voegelein F, Dubois J, et al: Structure-activity relationships of taxol and taxotere analogues. J Natl Cancer Inst Monogr 15: 79-82, 1993.
5. Liebmann I, Cook J A, Fisher J, et al: Changes in radiation survival curve parameters in human tumor and rodent cells exposed to Taxol (paclitaxel). Int J Radiat Oncol Biol Phys 29: 559-564, 1994. (Pubitemid 24187928)
6. Liebmann J, Cook JA, Fisher J, et al: In vitro studies of Taxol as radiosensitizer in human tumor cells. J Natl Cancer Inst 86: 441-446, 1994. (Pubitemid 24081876)
7. Steren A, Sevin BU, Perras J, et al: Taxol as radiation sensitizer: a flow cytometric study. Gynecol Oncol 50: 89-93, 1993. (Pubitemid 23235517)
8. Tishler RB, Schiff PB, Geard CR, et al: Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22: 613-617, 1992.
9. Minarik L and Hall EJ: Taxol in combination with acute and low dose rate irradiation. Radiother Oncol 32: 124-128, 1994. (Pubitemid 24270733)
10. Stromberg JS, Lee YJ, Armour EP, et al: Lack of radio-sensitisation after paclitaxel treatment of three human carcinoma cell lines. Cancer 75: 2262-2268, 1995.
11. Milas L, Hunter NR, Mason KA, et al: Enhancement of tumor radioresponse of a murine mammary carcinoma. Cancer Res 54: 3506-3510, 1994. (Pubitemid 24225974)
12. Zanelli GD, Quaia M, Robieux I, et al: Paclitaxel as a radiosensitizer: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer 33: 486-492, 1997. (Pubitemid 27168078)
13. Longnecker SM, Donehower RC, Cates AE, et al: High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71: 53-59, 1987. (Pubitemid 17003433)
14. Rathmann J, Leopold KA and Rigas JR: Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results. Semin Radiat Oncol 9 (suppl 1): 130-135, 1999. (Pubitemid 29190423)
15. Cox JD, Stetz J and Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31: 1341-1346, 1995.
16. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981. (Pubitemid 11167383)
17. Gianni L, Kearns CM, Giani A, et al: Non-linear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic-pharmacodinamic relationship in humans. J Clin Oncol 13: 180-190, 1995.
18. Choy H, Akerley W, Safran H, et al: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol 12: 2682-2686, 1994. (Pubitemid 24379656)
19. Choy H, Safran H, Akerley W, et al: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 4: 1931-1936, 1998. (Pubitemid 28369177)
20. Wolf M, Faoro C, Goerg C, et al: Paclitaxel and simultaneous radiation in the treatment of stage III A/B non-small cell lung cancer. Semin Oncol 23 (suppl 16): 108-112, 1996. (Pubitemid 27069000)
21. Marangolo M, Emiliani E, Rosti G, et al: Phase I/II study of paclitaxel and radiotherapy in non-small cell lung cancer. Semin Oncol 23 (suppl 16): 124-127, 1996. (Pubitemid 27069004)
22. Lau DH, Ryu JK, Gandara DR, et al: Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer. Semin Oncol 24 (suppl 12): S12-106-S12-109, 1997.
23. Vogt HG, Martin T, Kolotas C, et al: Simultanous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies. Semin Oncol 24 (suppl 12): S12-101-S12-105, 1997.
24. Kirkbride P, Gelmon K, Eisenhauer E, et al: A phase I/II study of paclitaxel (taxol) and concurrent radiotherapy in advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 39: 1107-1111, 1997. (Pubitemid 27506164)
25. Herscher LL, Hahn SM, Kroog G, et al: Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small cell lung cancer. J Clin Oncol 16: 635-641, 1998. (Pubitemid 28135610)
26. Dowell JE, Sinard R, Yardley DA, et al: Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers. Semin Radiat Oncol 9 (suppl 1): 97-101, 1999. (Pubitemid 29190418)
27. Oral EN, Bavbek S, Kizir A, et al: Preliminary analysis of a phase II study of paclitaxel and CHART in locally advanced non-small cell lung cancer. Lung Cancer 25: 191-198, 1999. (Pubitemid 29421626)
28. Antonia SJ, Wagner H, Williams C, et al: Concurrent paclitaxel/ cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung. Semin Oncol 22 (suppl 9): 34-37, 1995.
29. Belani CP, Aisner J, Bahri S, et al: Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease. Semin Oncol 23 (suppl 16): 113-116, 1996. (Pubitemid 27069001)
30. Greco FA, Stroup SL, Gray JR, et al: Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Clin Oncol 14: 1642-1648, 1996. (Pubitemid 26134223)
31. Choy H, Akerley W, Safran H, et al: Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. Semin Oncol 23 (suppl 16): 117-119, 1996. (Pubitemid 27069002)
32. Choy H, DeVore RF III, Hande KR, et al: Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. Semin Oncol 24 (suppl 12): S12-21-S12-26, 1997.
33. Comella G, Frasci G, Scoppa G, et al: Weekly paclitaxel/cisplatin with concurrent radiotherapy in patients with locally advanced non-small cell lung cancer: a phase I study. Semin Oncol 24 (suppl 12): S12-113-S12-116, 1997.
34. Langer CJ, Movsas B, Hudes R, et al: Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001. Semin Oncol 24 (suppl 12): S12-89-S12-95, 1997.
35. Socinsky MA, Rosenman JG, Halle J, et al: Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage III non-small cell lung carcinoma: a modified phase I-II trial. Cancer 92: 1213-1223, 2001.
36. Ratanatharathorn V, Lorvidhaya V, Maoleekoonpairoj S, et al: Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer 31: 257-265, 2001. (Pubitemid 32107021)
37. Lau D, Leigh B, Gandara D, et al: Twice weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/ paclitaxel consolidation for stage III non-small cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 19: 442-447, 2001. (Pubitemid 32112857)
38. Robert F, Spencer SA, Childs HA III, et al: Concurrent chemoradiation therapy with cisplatin paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. Lung Cancer 37: 189-199, 2002. (Pubitemid 34835688)
39. Nguyen NP, Leonardo JM, Karlsson U, et al: Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung cancer. Anticancer Res 22: 3429-3435, 2002. (Pubitemid 36132808)
40. Chang AY, Kim K, Glick J, et al:. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85: 388-394, 1993. (Pubitemid 23073157)
41. Arbuck S, Strauss H, Rowinsky EK, et al: A reassessment of cardiac toxicity associated with taxol. J Natl Cancer Inst Monogr 15: 117-130, 1993.